DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
MK-3682 is an investigational drug.
There have been 7 clinical trials for MK-3682. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2015.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis C, Chronic. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
Recent Clinical Trials for MK-3682
|Efficacy and Safety of MK-3682 + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)||Merck Sharp & Dohme Corp.||Phase 2|
|Efficacy and Safety of MK-3682 With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)||Merck Sharp & Dohme Corp.||Phase 2|
|Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)||Merck Sharp & Dohme Corp.||Phase 1|